BioSpace News Archive

Investigating feasibility of rapid, low-cost STI diagnostics development.

AVROBIO, Inc., a Phase 2 clinical-stage gene therapy company, reported financial results for the third quarter ended September 30, 2019 and provided a business update.

Part I of Adaptive RENEW Phase 3 Clinical Trial in Dry Eye Disease on Track for Completion in Fourth Quarter 2019

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced its operational and financial results for the third quarter ended September 30, 2019.

AgilVax Inc., announced that Joseph Patti, PhD, President and Chief Executive Officer, will present an overview of the Company and provide an update on its portfolio of targeted antibody-based therapies addressing multiple cancers at the NYC Oncology Investor Conference on November 12, 2019 at 5:30 PM The conference is being held at the Perkins Coie law firm, 1155 6th Ave, New York City, NY.

Meridian Bioscience, Inc. announced financial results for the fourth quarter and fiscal year ended September 30, 2019.

Theratechnologies Inc., a commercial-stage biopharmaceutical company, is pleased to announce that data presented at the 17th European AIDS Conference, currently being held in Basel, Switzerland, demonstrate that Trogarzo® remains safe and effective in patients having been on treatment for almost a decade.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today announced that five abstracts relating to the Company’s lead product candidate, rigosertib, were accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, FL

Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), today announced the completion of enrollment and dosing in its Phase 1 trial of INXN-4001, a multigenic investigational therapeutic candidate under evaluation for the treatment of heart failure, the leading cause of death worldwide.

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, will present its latest patient treatment data and key findings at the 15th Annual Neuroscience Education Insitute (NEI) Congress in Colorado, November 7-10, 2019.